Next Article in Journal
PESIN Conjugates for Multimodal Imaging: Can Multimerization Compensate Charge Influences on Cell Binding Properties? A Case Study
Next Article in Special Issue
Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFAlin-Modified Peptidic Radioligands Targeting Both Integrin αvβ3 and the MC1 Receptor—Suitable for the Specific Visualization of Melanomas?
Previous Article in Journal
Alpha2-Adrenoblockers Regulate Development of Oxidative Stress and Cognitive Behaviour of Rats under Chronic Acoustic Stress Conditions
Previous Article in Special Issue
Standardization of the [68Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer
Review

Update on PET Tracer Development for Muscarinic Acetylcholine Receptors

1
Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Wien, Austria
2
Department of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, University of Vienna, 1090 Wien, Austria
*
Author to whom correspondence should be addressed.
Academic Editor: Gerald Reischl
Pharmaceuticals 2021, 14(6), 530; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060530
Received: 7 May 2021 / Revised: 29 May 2021 / Accepted: 31 May 2021 / Published: 2 June 2021
The muscarinic cholinergic system regulates peripheral and central nervous system functions, and, thus, their potential as a therapeutic target for several neurodegenerative diseases is undoubted. A clinically applicable positron emission tomography (PET) tracer would facilitate the monitoring of disease progression, elucidate the role of muscarinic acetylcholine receptors (mAChR) in disease development and would aid to clarify the diverse natural functions of mAChR regulation throughout the nervous system, which still are largely unresolved. Still, no mAChR PET tracer has yet found broad clinical application, which demands mAChR tracers with improved imaging properties. This paper reviews strategies of mAChR PET tracer design and summarizes the binding properties and preclinical evaluation of recent mAChR tracer candidates. Furthermore, this work identifies the current major challenges in mAChR PET tracer development and provides a perspective on future developments in this area of research. View Full-Text
Keywords: molecular imaging; PET; tracer development; muscarinic acetylcholine receptors molecular imaging; PET; tracer development; muscarinic acetylcholine receptors
Show Figures

Graphical abstract

MDPI and ACS Style

Ozenil, M.; Aronow, J.; Millard, M.; Langer, T.; Wadsak, W.; Hacker, M.; Pichler, V. Update on PET Tracer Development for Muscarinic Acetylcholine Receptors. Pharmaceuticals 2021, 14, 530. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060530

AMA Style

Ozenil M, Aronow J, Millard M, Langer T, Wadsak W, Hacker M, Pichler V. Update on PET Tracer Development for Muscarinic Acetylcholine Receptors. Pharmaceuticals. 2021; 14(6):530. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060530

Chicago/Turabian Style

Ozenil, Marius, Jonas Aronow, Marlon Millard, Thierry Langer, Wolfgang Wadsak, Marcus Hacker, and Verena Pichler. 2021. "Update on PET Tracer Development for Muscarinic Acetylcholine Receptors" Pharmaceuticals 14, no. 6: 530. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060530

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop